In this series, we present selected articles presented at the SSO International Symposium of Regional Therapies at Jacksonville in 2018. The symposium, which was supported by the Society of Surgical Oncology, resulted in a record turnout and a great scientific discussion. In addition to laying grounds for scientific advances and collaboration, the meeting provided a family-friendly venue for networking, mentoring, and new ideas.
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Management of regional metastases with locoregional therapies has long been studied, and the year 2018 saw some remarkable advances. Evidence regarding the role of locoregional (HIPEC) therapy for peritoneal metastases of colorectal and ovarian origin was presented, which confirmed the efficacy of intraperitoneal therapy in ovarian tumors and in a select group of patients with peritoneal metastases from colorectal malignancies. The science behind melanoma immunotherapy has been supercharged, and the results of new trials of checkpoint inhibitors, elucidation of mechanisms of ''cold'' immune environments, IDO inhibitors, and inhibition of the MAP-Kinase pathway and the role of such therapies in adjuvant settings became mainstream. The field of liver metastases has matured in its understanding of catheter-based, regional therapies, and the evolution of modern therapies, such as ALPPS, two-stage liver resections, and liver transplants. Regional perfusion clinical trials remain active, and results are awaited.
The articles presented in this series focus on three themes: (1) the novel application of regional therapies to benign and malignant disease; (2) the role of perioperative outcomes and toxicity on oncological outcomes; and (3) patient-centered (and specific) optimization of therapies. A visual abstract summary of the articles is depicted in Fig. 1a-l .
With the rapid advancements in the field, it is time that regional therapies for locally advanced disease continue to advance and augment evolving therapies. Momentum in collaboration through the development of cooperative working groups, consensus conferences, and novel societies are reflective of the heightened interest in this field. Simultaneous with advances in the management of these diseases, advances in imaging, pathology, and translational research need to occur. Come join us in Phoenix this year to contribute to this evolving field! Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
